NEW YORK (TheStreet) -- TheStreet's Jim Cramer notes Agios Pharmaceuticals  (AGIO - Get Report) has doubled since he started recommending it.

He directs investors to an article in the New Yorker that explains how the company has a novel way of killing cancer in a targeted way by attacking the metabolism of cancer rather than carpet bombing the area. He says it is a unique company and points to positive results from Tuesday night that showed "out-and-out remission" of leukemia.

Cramer says he continues to believe Celgene  (CELG - Get Report) will buy this $3 billion company if it continues to perform as well as it has, even though he knows the CEO has a desire to build his own franchise. But Cramer says investors win either way. He thinks Agios is still not expensive if this drug works, and it appears to be working now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

AGIO Chart AGIO data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.